This common drug can decrease ventilation, ICU admission and death in COVID-19

Credit: CC0 Public Domain

In a new study, researchers found low-dose aspirin may reduce the need for mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized COVID-19 patients.

The research was conducted by a team at George Washington University.

As scientists learned about the connection between blood clots and COVID-19, they knew that aspirin—used to prevent stroke and heart attack—could be important for COVID-19 patients.

In the study, the team tested over 400 patients admitted from March to July 2020 to hospitals around the United States.

They found that aspirin use was linked to a decreased risk of mechanical ventilation (44% reduction), ICU admission (43% reduction), and in-hospital mortality (47% reduction).

Preliminary findings were first published as a preprint in fall 2020.

Since then, other studies have confirmed the impact aspirin can have on both preventing infection and reducing the risk for severe COVID-19 and death.

The team hopes that this study leads to more research on whether a causal relationship exists between aspirin use and reduced lung injury in COVID-19 patients.

They say aspirin is low-cost, easily accessible and millions are already using it to treat their health conditions.

Finding this association is a huge win for those looking to reduce risk from some of the most devastating effects of COVID-19.

The study is published in Anesthesia & Analgesia. One author of the study is Jonathan Chow, M.D.

Copyright © 2021 Knowridge Science Report. All rights reserved.